The Non-Fibrillar Side of Fibrosis: Contribution of the Basement Membrane, Proteoglycans, and Glycoproteins to Myocardial Fibrosis
- PMID: 31547598
- PMCID: PMC6956278
- DOI: 10.3390/jcdd6040035
The Non-Fibrillar Side of Fibrosis: Contribution of the Basement Membrane, Proteoglycans, and Glycoproteins to Myocardial Fibrosis
Abstract
The extracellular matrix (ECM) provides structural support and a microenvironmentfor soluble extracellular molecules. ECM is comprised of numerous proteins which can be broadly classified as fibrillar (collagen types I and III) and non-fibrillar (basement membrane, proteoglycans, and glycoproteins). The basement membrane provides an interface between the cardiomyocytes and the fibrillar ECM, while proteoglycans sequester soluble growth factors and cytokines. Myocardial fibrosis was originally only linked to accumulation of fibrillar collagens, but is now recognized as the expansion of the ECM including the non-fibrillar ECM proteins. Myocardial fibrosis can be reparative to replace the lost myocardium (e.g., ischemic injury or myocardial infarction), or can be reactive resulting from pathological activity of fibroblasts (e.g., dilated or hypertrophic cardiomyopathy). Contribution of fibrillar collagens to fibrosis is well studied, but the role of the non-fibrillar ECM proteins has remained less explored. In this article, we provide an overview of the contribution of the non-fibrillar components of the extracellular space of the heart to highlight the potential significance of these molecules in fibrosis, with direct evidence for some, although not all of these molecules in their direct contribution to fibrosis.
Keywords: basement membrane; extracellular matrix; fibrosis; heart; proteoglycans; remodeling.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Cellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy: changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans.J Mol Cell Cardiol. 1996 Aug;28(8):1591-608. doi: 10.1006/jmcc.1996.0150. J Mol Cell Cardiol. 1996. PMID: 8877770
-
Syndecans in heart fibrosis.Cell Tissue Res. 2016 Sep;365(3):539-52. doi: 10.1007/s00441-016-2454-2. Epub 2016 Jul 14. Cell Tissue Res. 2016. PMID: 27411689 Review.
-
Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression.Am J Physiol Cell Physiol. 2013 Mar 1;304(5):C393-402. doi: 10.1152/ajpcell.00347.2012. Epub 2012 Nov 21. Am J Physiol Cell Physiol. 2013. PMID: 23174564 Free PMC article. Review.
-
Differential impact of mechanical unloading on structural and nonstructural components of the extracellular matrix in advanced human heart failure.Transl Res. 2016 Jun;172:30-44. doi: 10.1016/j.trsl.2016.02.006. Epub 2016 Feb 23. Transl Res. 2016. PMID: 26963743
-
Organ fibrosis: beyond collagen I expression. Fibroblast phenotype and basement membrane proteins.Am J Physiol Cell Physiol. 2025 Jun 1;328(6):C2023-C2031. doi: 10.1152/ajpcell.00077.2025. Epub 2025 May 12. Am J Physiol Cell Physiol. 2025. PMID: 40353336 Free PMC article. Review.
Cited by
-
Rescue of mitochondrial dysfunction through alteration of extracellular matrix composition in barth syndrome cardiac fibroblasts.Biomaterials. 2025 Apr;315:122922. doi: 10.1016/j.biomaterials.2024.122922. Epub 2024 Oct 26. Biomaterials. 2025. PMID: 39509858
-
Circulating microRNAs in predicting fibrosis in hypertrophic cardiomyopathy: A systematic review.World J Cardiol. 2025 May 26;17(5):106123. doi: 10.4330/wjc.v17.i5.106123. World J Cardiol. 2025. PMID: 40496394 Free PMC article.
-
Anti-fibrosis effect of astragaloside IV in animal models of cardiovascular diseases and its mechanisms: a systematic review.Pharm Biol. 2025 Dec;63(1):250-263. doi: 10.1080/13880209.2025.2488994. Epub 2025 Apr 22. Pharm Biol. 2025. PMID: 40260854 Free PMC article.
-
Persistent Transcriptome Alterations in Zebrafish Embryos After Discontinued Opioid Exposure.Int J Mol Sci. 2025 May 19;26(10):4840. doi: 10.3390/ijms26104840. Int J Mol Sci. 2025. PMID: 40429979 Free PMC article.
-
Post-myocardial infarction fibrosis: Pathophysiology, examination, and intervention.Front Pharmacol. 2023 Mar 28;14:1070973. doi: 10.3389/fphar.2023.1070973. eCollection 2023. Front Pharmacol. 2023. PMID: 37056987 Free PMC article. Review.
References
-
- De Boer R.A., De Keulenaer G., Bauersachs J., Brutsaert D., Cleland J.G., Diez J., Du X.J., Ford P., Heinzel F.R., Lipson K.E., et al. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur. J. Heart Fail. 2019;21:272–285. doi: 10.1002/ejhf.1406. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources